
Sign up to save your podcasts
Or


In Episode 43 of Hims House, hosts Jonathan Stern and Patrick Lester (Bayside) sit down with Dr. William Seeds, a board-certified orthopedic surgeon and pioneer in peptide therapy. Dr. Seeds shares how a personal tragedy led him to explore the power of peptides and why he believes they will redefine the future of medicine. The conversation covers the fundamentals of peptides, why they are often called "magical" drugs, and the skepticism they sometimes face. The trio also explores why the U.S. lags behind Europe and Asia in adoption, and the historical influence of Big Pharma. The episode closes with Dr. Seeds sharing predictions on how Hims could legally enter the peptide market, what products they may launch first, and how the field will evolve over the next decade.
00:00 - Introduction
01:31 - Dr. Seeds’ personal journey into peptides
05:28 - Peptides 101
13:44 - Legal & Regulatory Barriers
17:00 - Response to Eric Topol's recent article
25:29 - The U.S. legal landscape
35:56 - Potential FDA crackdown bad actors
36:29 - Risks facing physicians and vendors
37:19 - What’s next in peptide policy
38:43 - Patents
40:51 - How Big Pharma shapes regulation
44:37 - Peptide adoption worldwide
47:06 - How will Hims enter the market?
56:45 - The two, five and ten-year outlook
01:02:55 - Final takeaways
By Jonathan Stern5
77 ratings
In Episode 43 of Hims House, hosts Jonathan Stern and Patrick Lester (Bayside) sit down with Dr. William Seeds, a board-certified orthopedic surgeon and pioneer in peptide therapy. Dr. Seeds shares how a personal tragedy led him to explore the power of peptides and why he believes they will redefine the future of medicine. The conversation covers the fundamentals of peptides, why they are often called "magical" drugs, and the skepticism they sometimes face. The trio also explores why the U.S. lags behind Europe and Asia in adoption, and the historical influence of Big Pharma. The episode closes with Dr. Seeds sharing predictions on how Hims could legally enter the peptide market, what products they may launch first, and how the field will evolve over the next decade.
00:00 - Introduction
01:31 - Dr. Seeds’ personal journey into peptides
05:28 - Peptides 101
13:44 - Legal & Regulatory Barriers
17:00 - Response to Eric Topol's recent article
25:29 - The U.S. legal landscape
35:56 - Potential FDA crackdown bad actors
36:29 - Risks facing physicians and vendors
37:19 - What’s next in peptide policy
38:43 - Patents
40:51 - How Big Pharma shapes regulation
44:37 - Peptide adoption worldwide
47:06 - How will Hims enter the market?
56:45 - The two, five and ten-year outlook
01:02:55 - Final takeaways

3,384 Listeners

3,072 Listeners

937 Listeners

102 Listeners

278 Listeners

192 Listeners

300 Listeners

2,112 Listeners

9,957 Listeners

107 Listeners

247 Listeners

807 Listeners

169 Listeners

405 Listeners

512 Listeners